Prosecution Insights
Last updated: November 04, 2026

Landrace Bioscience Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Landrace Bioscience Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The record shows 1 distinct examiner and 1 distinct art unit, keeping the prosecution activity within one defined examination setting. PURDY, KYLE A is the busiest examiner, with 1 pending matter.

Counsel can therefore concentrate on a single outstanding action and its biotechnology and pharmaceutical context. No separate examiner or art-unit coordination is indicated by the profile. The response should connect claim scope, technical explanations, and available disclosure to the issues presented by the identified examiner.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PURDY, KYLE A 1 40.9% +35.7%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17774089 SELF-EMULSIFYING CANNABINOID FORMULATION AND METHOD PURDY, KYLE A —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17774089 SELF-EMULSIFYING CANNABINOID FORMULATION AND METHOD PURDY, KYLE A —

Top Art Units

Art UnitApps
1611 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17774089 SELF-EMULSIFYING CANNABINOID FORMULATION AND METHOD PURDY, KYLE A 1611 §103§112 Non-Final OA — Pending May 03, 2022

Managing Landrace Bioscience Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Landrace Bioscience Inc. have?

Landrace Bioscience Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Landrace Bioscience Inc. applications?

Kyle A Purdy has the most, with 1 of Landrace Bioscience Inc.'s pending office actions.

What technology area are Landrace Bioscience Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month